Advanced Therapy Medicinal Products Market - Industry Structure Evaluation, Demand Drivers Analysis, Regional Growth Analysis and Identification, Competitive Positioning Review & Global Market Size Forecast to 2032
Overview
Global Advanced Therapy Medicinal Products Market size was valued at USD 16.60 Bn. in 2025 and the total Advanced Therapy Medicinal Products revenue is expected to grow by 13.2 % from 2026 to 2032, reaching nearly USD 39.55 Bn.
Advanced Therapy Medicinal Products Market Overview:
ATMPs (advanced therapeutic medical products) are medicines of human that are based on the genetic, tissue makeup of human beings. It provides the whole new avenues for the treatment of sicknesses which are rare and critical injuries. Medical products in advanced treatment are progressive therapies that rely on high-quality treatment, extensive cell treatment, and tissue-constructed things. As a consequence, the worldwide advanced treatment medical goods market is projected to grow during the forecast period. ATMPs are pharmaceuticals that act on live cells or dynamic hereditary materials to provide innovative therapeutic options for a variety of infections, both acute and chronic.
To know about the Research Methodology :- Request Free Sample Report
Advanced Therapy Medicinal Products Market Dynamics:
A Booming Industry Driven by Innovation and Investment
The introduction of Advanced Therapy Medicinal Products (ATMPs) has changed the pharmaceutical business and the panorama of medical treatment. It has laid the foundation for novel treatments for incurable illnesses and cancers of different kinds. The market is being driven by the success of products like Kymriah, Zolgensma, and others.
This is likely to propel expenditure in advanced treatment research and development for SARS-CoV2 infections. Furthermore, an increasing number of clinical trials including Mesenchymal Stromal/Stem Cells (MSCs) have recently been filed as a novel therapy paradigm for SARS-CoV-2 infection. These treatments have exhibited encouraging outcomes in research programs as a therapeutic method, contributing to the marketspace's organic revenue creation which boosts the Cell Therapy Treatments Market.
The market for advanced treatment medical products has risen exponentially in recent years. This industry is expected to become more competitive as a growing number of businesses enter the market. Furthermore, new Advanced Therapy Medicinal Products (ATMP) approvals have boosted this sector's growth. Market participants are employing a variety of methods in order to maintain their market position. The current trend in this sector is collaborations with contract manufacturing firms. Due to increased Research and Development activity in this sector, contract manufacturing organizations (CMOs) are seeing a surge in demand for their services.
Moreover, tie-ups with Contract research organizations and contract manufacturing organizations are economical, licensed, and offer safety and security towards the end product. Hence, this factor is likely to motivate Advanced Therapy Medicinal Products Market growth in the future.
Gene Therapy Products Market Poised for Growth as Protein and Small Molecule-Based Research Intensifies
Various protein and small molecule-based research and design firms have begun to focus on adoptive cell T treatments. For example, the U.S. FDA approved Bristol Myers Squibb's Abecma (idecabtagene vicleucel) - a cell-based gene therapy medicinal product designed for the treatment of patients with multiple myeloma in March 2021, through a partnership with Bluebird-Bio. As a result, the demand for the Gene Therapy Products Market is increasing.
Investments in Advanced Therapy Medicinal Products and an increase in financing is expected to deliver plenty of growth opportunities in the market. T-cell therapies are supported financially by grants awarded to university hospitals. Some market players have undertaken in-house production of therapies, and several players prefer service from third-party providers, including contract manufacturing organizations. On the other side, numerous companies have marked their presence in the market just by obtaining small and emerging CAR T-cell therapy developers. Some notable and recent examples include the purchases of Kite Pharma by Gilead Life Science, AveXis by Novartis, and Juno Therapeutics by Celgene. Therefore, the factors above boost the market growth.
Advanced Therapy Medicinal Products Market Segment Analysis:
The tissue-engineered product segment is anticipated to adhere to the growth of the Advanced Therapy Medicinal Products Market.
Based on the Therapy Type, The tissue-engineered product category led the market accounting for 39.0% of revenue share. The adoption of tissue-engineered products or processes as an important element of medicine and treatment procedures, particularly in therapies that demand functional recovery of any sick or wounded area of the body, may be ascribed to this dominance. The amount of publications, research papers, clinical trials, and translational products has increased dramatically in recent years, indicating that this area has gained substantial popularity which has propelled the Tissue Engineered Products Market. Furthermore, the segment's expansion is aided by ongoing advances in technology and products to advance the tissue engineering process. For example, a group of researchers at the University of Illinois Chicago presented a unique hydrogel-shaped-changing 4D material in February 2021 that can change form in response to physiological inputs.
The CAR-T treatment sector, on the other hand, is getting popular in the market and is anticipated to grow at the strongest rate throughout the projection period. Key firms including Novartis AG, Gilead Sciences, Inc., and Bristol-Myers Squibb are emphasizing increasing the global reach of their CAR-T therapies which increases the demand for the CAR-T Cell Therapies Market. For example, Novartis AG revealed that the Health Sciences Authority has authorized Kymriah as Singapore's first commercially licensed CAR-T treatment. It is expected that the growth by other segments such as cell therapy which is segmented into two different sub-segments i.e. stem cell therapy and non-stem cell therapy. Stem cell therapy promotes the healing response of diseased, injured tissue using stem cells and due to this Stem Cell-based Therapies Market is in demand. There are physical therapy, occupational therapy, speech therapy, and other types of rehabilitation that come under neurological disorder therapies which increases the demand for the neurological disorder therapies market.
Based on the Distribution Channel,
Hospital Pharmacies dominated the market in the year 2025 with almost 53% in terms of revenue share and is expected to dominate the ATMP market during the forecast period. Other segments such as retail pharmacies and online pharmacies are gaining some popularity in the market. The expansion of Retail pharmacies is expected throughout the forecast period, particularly for less complex products. Online pharmacies are leveraging and increasing its demand, as the convenience and accessibility to reach patients in remote areas is also increasing. As a result, the demand for the Advanced Therapy Medicinal Products(ATMP) Industry and Advanced Therapy Clinical Trials Market as well.
Advanced Therapy Medicinal Products Market Regional Insights:
North America dominates the Advanced Therapy Medicinal Products market driven by strong biotechnology innovation and favorable regulatory support
North America holds the largest share of the global Advanced Therapy Medicinal Products (ATMP) market, supported by a well-established biotechnology ecosystem, substantial investments in regenerative medicine, and increasing clinical trial activity. The United States leads the region due to the presence of major biopharmaceutical companies, advanced healthcare infrastructure, and strong funding for gene therapy, cell therapy, and tissue-engineered products. Favorable regulatory pathways, rising approvals for innovative therapies, and growing collaborations between research institutions and industry players continue to strengthen the regional market. Additionally, increasing prevalence of rare genetic disorders, cancer, and chronic diseases is accelerating the adoption of advanced therapeutic solutions.
Europe holds a significant market share supported by a robust regulatory framework and expanding ATMP commercialization
Europe represents a major market for Advanced Therapy Medicinal Products, driven by increasing investments in regenerative medicine, supportive regulatory policies, and growing research and development activities. Countries such as Germany, the UK, France, Italy, Spain, and the Netherlands are witnessing rising adoption of gene and cell therapies across oncology, neurology, ophthalmology, and rare disease treatments. The region benefits from strong academic research, government funding, and collaborations between biotechnology companies and healthcare providers. Furthermore, expanding manufacturing capabilities and increasing commercialization of ATMPs are contributing to sustained market growth.
Asia-Pacific is expected to witness the fastest growth during the forecast period owing to increasing healthcare investments and biotechnology advancements
Asia-Pacific is projected to register the highest CAGR during the forecast period due to rising healthcare expenditure, expanding biotechnology and pharmaceutical industries, and increasing government support for regenerative medicine. Countries such as China, Japan, South Korea, India, and Australia are investing heavily in stem cell research, gene editing technologies, and advanced biologics manufacturing. Growing clinical trial activities, improving regulatory frameworks, and increasing awareness of personalized medicine are further driving the adoption of Advanced Therapy Medicinal Products across the region.
Latin America and the Middle East & Africa are emerging markets with growing investments in advanced healthcare technologies
Latin America and the Middle East & Africa are anticipated to experience steady market growth due to improving healthcare infrastructure, increasing access to innovative therapies, and rising investments in biotechnology research. Countries such as Brazil, Mexico, the UAE, Saudi Arabia, and South Africa are gradually expanding their capabilities in regenerative medicine and advanced biologics through strategic collaborations and government initiatives. Although challenges related to high treatment costs, limited manufacturing capacity, and evolving regulatory frameworks remain, increasing awareness and healthcare modernization efforts are expected to create new opportunities for the Advanced Therapy Medicinal Products market during the forecast period.
Global Advanced Therapy Medicinal Products Market Recent Developments:
| Date | Recent Development |
| 05 Dec 2025 | Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG received European Commission approval for CASGEVY® (exagamglogene autotemcel) for the treatment of transfusion-dependent beta thalassemia, expanding access to the first approved CRISPR-based gene-editing therapy in Europe. |
| 30 Jul 2025 | Bristol Myers Squibb received U.S. FDA approval for Abecma® to expand its indication to earlier lines of treatment for adults with relapsed or refractory multiple myeloma, strengthening its CAR-T cell therapy portfolio. |
| 18 Apr 2025 | Orchard Therapeutics plc announced continued global commercialization initiatives for Lenmeldy®, expanding patient access to its gene therapy for metachromatic leukodystrophy through collaborations with treatment centers. |
| 28 Mar 2025 | Porton Advanced entered into a strategic partnership with Eureka Therapeutics, Inc. to accelerate the development and manufacturing of next-generation T-cell therapies for solid tumors and hematologic malignancies. |
| 31 Jan 2025 | Johnson & Johnson completed the acquisition of Intra-Cellular Therapies, Inc., strengthening its innovative medicines portfolio and expanding capabilities in advanced therapeutic development. |
| 19 Dec 2024 | bluebird bio, Inc. received European Commission approval for LYFGENIA® commercialization activities and continued expansion of gene therapy treatment infrastructure for sickle cell disease across key European markets. |
Competitive Landscape-Advanced Therapy Medical Products Markets
The global Advanced Therapy Medicinal Products (ATMP) market is highly competitive and innovation-driven, with leading biopharmaceutical companies, biotechnology firms, and contract development and manufacturing organizations (CDMOs) focusing on expanding their cell therapy, gene therapy, and tissue-engineered product portfolios. Market participants are investing heavily in research and development, clinical trials, advanced manufacturing technologies, and regulatory approvals to accelerate the commercialization of next-generation therapies. Strategic initiatives such as mergers and acquisitions, licensing agreements, technology collaborations, and manufacturing capacity expansions are enabling companies to strengthen their global presence and address the growing demand for personalized and regenerative medicines. The increasing adoption of gene-editing technologies, viral vector platforms, and automation in cell manufacturing is further intensifying competition within the market.
Companies are also prioritizing scalable manufacturing processes, supply chain optimization, and strategic partnerships with academic institutions, healthcare organizations, and research centers to enhance product development and accelerate market access. In addition, investments in allogeneic cell therapies, CAR-T cell therapies, gene-editing platforms, and advanced tissue engineering technologies are shaping the competitive landscape. As regulatory agencies continue to introduce accelerated approval pathways for innovative therapies targeting rare diseases, oncology, and genetic disorders, market participants are focusing on expanding their clinical pipelines and global commercialization strategies. Key companies operating in the global Advanced Therapy Medicinal Products market include Novartis AG, Gilead Sciences, Inc. (Kite Pharma), Bristol Myers Squibb Company, Bluebird Bio, Inc., Bayer AG, Johnson & Johnson, F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Legend Biotech Corporation, and BioMarin Pharmaceutical Inc., all of which continue to strengthen their market positions through innovation, strategic collaborations, manufacturing expansion, and regulatory approvals.
Advanced Therapy Medicinal Products Market Scope: Inquire before buying
| Advanced Therapy Medicinal Products Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2032 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | USD 16.60 Bn. |
| Forecast Period 2026 to 2032 CAGR: | 13.2% | Market Size in 2032: | USD 39.55 Bn. |
| Segments Covered: | By Therapy Type | Cell Therapy Stem Cell Therapy Non-stem Cell Therapy CAR-T Therapy Gene Therapy Tissue Engineered Product |
|
| By Disease Type | Alzheimer’s Cystic Fibrosis Muscular Dystrophies Hemophilia |
||
| By Distribution Channel | Hospital Pharmacy Retail Pharmacy Online Pharmacy |
||
Advanced Therapy Medicinal Products Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Advanced Therapy Medicinal Products Market Key Players:
North America
- Sarepta Therapeutics, Inc. – United States
- Bluebird Bio, Inc. – United States
- Rocket Pharmaceuticals, Inc. – United States
- Regenxbio Inc. – United States
- Krystal Biotech, Inc. – United States
- Solid Biosciences Inc. – United States
- Passage Bio, Inc. – United States
- Voyager Therapeutics, Inc. – United States
- Gilead Sciences, Inc. (Kite Pharma) – United States
- Bristol Myers Squibb Company – United States
- Fate Therapeutics, Inc. – United States
- Allogene Therapeutics, Inc. – United States
- Century Therapeutics, Inc. – United States
- Lyell Immunopharma, Inc. – United States
- ArsenalBio Inc. – United States
- Atara Biotherapeutics, Inc. – United States
- Organogenesis Holdings Inc. – United States
- Vericel Corporation – United States
- BioCardia, Inc. – United States
- Lineage Cell Therapeutics, Inc. – United States
- Editas Medicine, Inc. – United States
- Intellia Therapeutics, Inc. – United States
- Beam Therapeutics Inc. – United States
- Caribou Biosciences, Inc. – United States
- Precision BioSciences, Inc. – United States
- Prime Medicine, Inc. – United States
- Arbor Biotechnologies, Inc. – United States
- Metagenomi, Inc. – United States
- Scribe Therapeutics Inc. – United States
- Thermo Fisher Scientific Inc. – United States
- Charles River Laboratories International, Inc. – United States
- Resilience – United States
- Andelyn Biosciences – United States
- Kincell Bio – United States
- ElevateBio – United States
Europe
- Orchard Therapeutics plc – United Kingdom
- uniQure N.V. – Netherlands
- Oxford Biomedica plc – United Kingdom
- Lonza Group AG – Switzerland
- Sartorius AG – Germany
- Cellectis S.A. – France
- CRISPR Therapeutics AG – Switzerland
- Autolus Therapeutics plc – United Kingdom
- Medigene AG – Germany
- Miltenyi Biotec – Germany
- CO.DON AG – Germany
- CellProthera SAS – France
- Bone Therapeutics SA – Belgium
- ReNeuron Group plc – United Kingdom
- AGC Biologics – Denmark
- Rentschler Biopharma SE – Germany
- Cell and Gene Therapy Catapult – United Kingdom
Asia Pacific
- Takara Bio Inc. – Japan
- Daiichi Sankyo Company, Limited – Japan
- Kyowa Kirin Co., Ltd. – Japan
- JCR Pharmaceuticals Co., Ltd. – Japan
- Healios K.K. – Japan
- PHC Holdings Corporation – Japan
- FUJIFILM Diosynth Biotechnologies – Japan
- CMIC Holdings Co., Ltd. – Japan
- JW Therapeutics – China
- Legend Biotech Corporation – China
- CARsgen Therapeutics Holdings Limited – China
- IASO Biotherapeutics – China
- WuXi Advanced Therapies – China
- BGI Genomics Co., Ltd. – China
- GC Cell Corporation – South Korea
- ToolGen Inc. – South Korea
- GenKORE Inc. – South Korea
- MEDIPOST Co., Ltd. – South Korea
- Anterogen Co., Ltd. – South Korea
- Samsung Biologics – South Korea
Others
Frequently Asked Questions:
1] What segments are covered in the Global Advanced Therapy Medicinal Products Market report?
Ans. The segments covered in the Advanced Therapy Medicinal Products Market report are based on Therapy Type, Disease Type, and Distribution Channel, and Region.
2] Which region is expected to hold the highest share of the Global Advanced Therapy Medicinal Products Market?
Ans. The North American region is expected to hold the highest share of the Advanced Therapy Medicinal Products Market. The United States is expected to lead the North American market and is expected to grow at a CAGR of 8.2% over the forecast period.
3] What is the market size of the Global Advanced Therapy Medicinal Products Market by 2032?
Ans. The market size of the Advanced Therapy Medicinal Products Market by 2032 is expected to reach US$ 39.55 Bn.
4] What is the forecast period for the Global Advanced Therapy Medicinal Products Market?
Ans. The forecast period for the Advanced Therapy Medicinal Products Market is 2026-2032
5] What was the market size of the Global Advanced Therapy Medicinal Products Market in 2025?
Ans. The market size of the Advanced Therapy Medicinal Products Market in 2025 was valued at US$ 16.60 Bn.